CenterBook Partners LP Raises Position in Charles River Laboratories International, Inc. $CRL

CenterBook Partners LP grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 534.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,794 shares of the medical research company’s stock after buying an additional 20,041 shares during the quarter. CenterBook Partners LP’s holdings in Charles River Laboratories International were worth $3,723,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in Charles River Laboratories International during the 2nd quarter valued at $76,952,000. National Bank of Canada FI lifted its holdings in shares of Charles River Laboratories International by 1,179.5% during the second quarter. National Bank of Canada FI now owns 434,868 shares of the medical research company’s stock valued at $65,983,000 after purchasing an additional 400,881 shares in the last quarter. Balyasny Asset Management L.P. boosted its position in shares of Charles River Laboratories International by 722.5% during the second quarter. Balyasny Asset Management L.P. now owns 434,226 shares of the medical research company’s stock valued at $65,885,000 after buying an additional 381,432 shares during the last quarter. Ariel Investments LLC increased its holdings in Charles River Laboratories International by 28.6% in the 2nd quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock worth $214,751,000 after buying an additional 314,572 shares in the last quarter. Finally, LSV Asset Management increased its holdings in Charles River Laboratories International by 1,773.0% in the 3rd quarter. LSV Asset Management now owns 297,800 shares of the medical research company’s stock worth $46,594,000 after buying an additional 281,900 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Key Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Company forecasts stronger 2026 profit driven by improving demand for drug‑development services, supporting the view that revenues and margins should recover. Charles River forecasts upbeat 2026 profit on improved demand for drug development services
• Positive Sentiment: Q4 results beat expectations: revenue ~ $994M and EPS $2.39 beat consensus, and margins expanded — a near‑term fundamental positive. Charles River Laboratories (NYSE: CRL) beats Q4 CY2025 sales expectations
• Positive Sentiment: Management projects up to ~9% EPS growth for 2026, citing a new CEO, targeted acquisitions and cost‑savings initiatives to expand margins — a constructive catalyst for longer‑term earnings. Charles River projects up to 9% EPS growth in 2026 as new CEO, acquisitions, and cost savings drive margin expansion
• Neutral Sentiment: Company announced executive appointments that support the strategic shift; impact depends on execution of cost and M&A plans. Charles River Laboratories Announces Executive Appointments
• Neutral Sentiment: Detailed Q4 earnings call transcript and slide deck are available for investors to assess pipeline, book‑to‑bill trends and 2026 assumptions. Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Organic growth fell across all segments and revenue was down ~0.8% year‑over‑year, raising questions about near‑term demand recovery and the pace of margin improvement. CRL Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: EPS declined versus the prior year and the firm still showed a negative net margin in the quarter, which may keep some investors cautious despite the beat. Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates

Charles River Laboratories International Trading Down 0.2%

Shares of CRL stock opened at $158.28 on Thursday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10. The company has a market cap of $7.79 billion, a price-to-earnings ratio of -101.46, a PEG ratio of 4.80 and a beta of 1.63. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $228.88. The firm has a fifty day moving average price of $201.46 and a 200-day moving average price of $179.44.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. The company had revenue of $994.23 million for the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.Charles River Laboratories International’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period last year, the firm earned $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Wall Street Zen raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Evercore increased their price objective on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. JPMorgan Chase & Co. lifted their target price on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Morgan Stanley set a $185.00 price target on Charles River Laboratories International in a report on Monday, December 1st. Finally, Argus set a $200.00 price target on Charles River Laboratories International in a research note on Monday, November 17th. Ten analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $209.46.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.